UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 21, 2015
Commission File Number: 000-17119
QuantRx Biomedical Corporation
(Exact name of small business issuer as specified in its charter)
(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
(State or other jurisdiction of incorporation or organization)
330202574
(IRS Employer Identification No.)
(IRS Employer Identification No.)
10190 SW 90th Avenue, No. 4690, Tualatin, Oregon 97123
(Address of principal executive offices)
(Address of principal executive offices)
503-575-9385
(Registrant's Telephone number)
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
QuantRx Biomedical Corporation (the "Company") announced that William Fleming, its President, Chief Scientific Officer and a director, unexpectedly passed away on March 21, 2015. The Board of Directors is currently searching for a successor to manage the Company as it executes is business plan. In the interim, the Company will be managed by its Chief Executive Officer, with assistance from its Board of Directors and outside advisors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
QuantRx Biomedical Corporation |
Date: March 26, 2015
By: | /s/ Dr. Shalom Hirshman |
Name: Dr. Shalom Hirshman | |
Title: Chief Executive Officer |